Wells Fargo’s Pear Therapeutics, Inc. Class A Common Stock PEAR Stock Holding History

Wells Fargo’s Portfolio PEAR Stock Details PEAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14,441	Closed	-$3.68K	–	7798
2023 Q1	$3.68K	Buy	14,441 +10,122	+234%	+$9.14K	﹤0.01%	6119
2022 Q4	$5.1K	Buy	4,319 +2,059	+91%	+$4.33K	﹤0.01%	5765
2022 Q3	$5K	Buy	2,260 +2,029	+878%	+$3.44K	﹤0.01%	5941
2022 Q2	$0	Buy	231 +19	+9%	+$74	﹤0.01%	7861
2022 Q1	$1K	Buy	+212	New	+$963	﹤0.01%	6918

Wells Fargo's PEAR Position: Q2 2023 in Review

Wells Fargo sold out of Pear Therapeutics, Inc. Class A Common Stock (PEAR) in Q2 2023, closing a stake of 14,441 shares — an estimated $3.68K sold.

Wells Fargo first reported a position in PEAR in Q1 2022 and held it in 5 quarters. The position peaked at $5.1K in Q4 2022. 1 fund tracked by Wall St. Rank holds PEAR as of Q2 2023.

Wells Fargo reported no remaining Pear Therapeutics, Inc. Class A Common Stock position as of Q2 2023 after selling out during the quarter.
Wells Fargo sold 14,441 Pear Therapeutics, Inc. Class A Common Stock shares in Q2 2023, an estimated $3.68K.
Wells Fargo first reported a position in Pear Therapeutics, Inc. Class A Common Stock in Q1 2022 and held it in 5 quarters.
Wells Fargo's Pear Therapeutics, Inc. Class A Common Stock position peaked at $5.1K in Q4 2022.
1 fund tracked by Wall St. Rank held Pear Therapeutics, Inc. Class A Common Stock as of Q2 2023.

Based on Wells Fargo's 13F filing for Q2 2023, filed 15 Aug 2023.